Yalcin, A. D. Et Al. 2014. Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-up. CLINICAL LABORATORY , vol.60, no.9 , 1561-1564.

Yalcin, A. D., Gorczynski, R. M., ÇİLLİ, A., & Strauss, L., (2014). Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-up. CLINICAL LABORATORY , vol.60, no.9, 1561-1564.

Yalcin, Arzu Et Al. "Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-up," CLINICAL LABORATORY , vol.60, no.9, 1561-1564, 2014

Yalcin, Arzu D. Et Al. "Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-up." CLINICAL LABORATORY , vol.60, no.9, pp.1561-1564, 2014

Yalcin, A. D. Et Al. (2014) . "Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-up." CLINICAL LABORATORY , vol.60, no.9, pp.1561-1564.

@article{article, author={Arzu Didem Yalcin Et Al. }, title={Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-up}, journal={CLINICAL LABORATORY}, year=2014, pages={1561-1564} }